Pulmatrix touts Ph1 data for inhaled COPD therapy
Pulmatrix (NSDQ:PULM) touted data today from a dose-ranging Phase I trial of its once-daily inhaled therapy designed for people with chronic obstructive pulmonary disease. The company’s product is a reformulation of tiotropium bromide, the active component in Boehringer Ingelheim’s blockbuster drug, Spiriva. Get the full story at our sister site, Drug Delivery Business News. The post Pulmatrix touts Ph1 data for inhaled COPD therapy appeared first on MassDevice.
Conditions: Pulmonary Disease, Chronic Obstructive; Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome; Small Airway Disease; Quality of Life Intervention: Drug: Budesonide(160ug) and Formoterol(4.5ug) bid Sponsor: Zhujiang Hospital Not yet recruiting
Condition: Chronic Obstructive Pulmonary Disease Interventions: Other: energy conservation technique; Other: control session Sponsor: Groupe Hospitalier du Havre Not yet recruiting
Condition: COPD Exacerbation Interventions: Device: Nasal High Flow Therapy; Other: Standard care Sponsors: Marieke Duiverman; Rijnstate Hospital; Medisch Spectrum Twente; Albert Schweitzer Hospital; Technical University of Twente; Fisher and Paykel Healthcare; VIVISOL Not yet recruiting
Authors: Lenferink A, van der Palen J, Effing T PMID: 29909705 [PubMed - as supplied by publisher]
Pharmacoepidemiology and Drug Safety, EarlyView.
CONCLUSIONS: The THK shall expect more patients with acute wheezing after extremes of weather. Minimum temperature has been consistently correlated with the exacerbation of respiratory symptoms in the past studies in other countries as well. Hence, prescribing the inhalation of more drugs on unusually cold days (prophylactically) may help prevent acute exacerbation of wheezing in patients on treatment for asthma and COPD. PMID: 29912647 [PubMed - in process]
CONCLUSIONS: This study provides detailed information that facilitates studying CRS and its main phenotypes. However, patient distribution of this study does not necessarily reflect disease distribution in the general population. PMID: 29911211 [PubMed - as supplied by publisher]
Conditions: Smoking Cessation; Chronic Obstructive Pulmonary Disease (COPD); Healthy; Microbial Colonization Intervention: Behavioral: Smoking cessation Sponsors: Research Center Borstel; Leibniz Institute DSMZ - German Collection of Microorganisms and Cell Cultures; Leibniz Institute of Photonic Technology (IPHT), Jena, Germany; Technical University of Munich, Helmholtz Center Munich, Munich Germany Recruiting
TUESDAY, June 19, 2018 -- For adults with chronic obstructive pulmonary disease (COPD), acute exacerbations are associated with increased risk of myocardial infarction and ischemic stroke, according to a study published online May 3 in the Annals of...